This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study of Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids (MILLY)

This study has been completed.
Information provided by (Responsible Party):
Genentech, Inc. Identifier:
First received: June 29, 2009
Last updated: November 25, 2016
Last verified: November 2016
This is a randomized, double-blind, placebo-controlled study to evaluate the effects of lebrikizumab in patients with asthma who remain inadequately controlled while on chronic therapy with inhaled corticosteroids (ICS).

Condition Intervention Phase
Asthma Drug: lebrikizumab (MILR1444A) Drug: placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids

Resource links provided by NLM:

Further study details as provided by Genentech, Inc.:

Primary Outcome Measures:
  • Change in forced expiratory volume in 1 second (FEV1) [ Time Frame: From baseline to Week 12 ]

Secondary Outcome Measures:
  • Change in pre-bronchodilator FEV1 [ Time Frame: From baseline to Week 24 ]
  • Change in quality of life and symptom scores [ Time Frame: From baseline to Week 12 ]
  • Change in peak flow [ Time Frame: From baseline to Week 1 ]
  • Rate of asthma exacerbations [ Time Frame: During the 24 week treatment period ]
  • Change in rescue medication use [ Time Frame: From baseline to Week 1 ]
  • Frequency and severity of adverse events [ Time Frame: Through study completion or early study discontinuation ]
  • Incidence of human anti-therapeutic antibodies (ATA) [ Time Frame: At the end of the follow-up period ]

Enrollment: 218
Study Start Date: July 2009
Study Completion Date: September 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: lebrikizumab (MILR1444A)
Subcutaneous repeating dose
Placebo Comparator: 2 Drug: placebo
Subcutaneous repeating dose


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Body weight 40 kg--150 kg
  • Chest radiograph with no evidence of clinically significant abnormality
  • Uncontrolled asthma

Exclusion Criteria:

  • Asthma exacerbation during screening
  • Known malignancy
  • Known immunodeficiency
  • Pre-existing lung disease other than asthma
  • Uncontrolled clinically significant medical disease
  • Current smoker
  • History of substance abuse that may impair or risk the patient's full participation in the study, in the judgment of the investigator
  • Prior allergic reaction to a monoclonal antibody
  • Patients (men and women) of reproductive potential who are not willing to use contraception
  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00930163

Sponsors and Collaborators
Genentech, Inc.
Study Director: Michelle Freemer, M.D. Genentech, Inc.
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Genentech, Inc. Identifier: NCT00930163     History of Changes
Other Study ID Numbers: ILR4646g
Study First Received: June 29, 2009
Last Updated: November 25, 2016

Keywords provided by Genentech, Inc.:
Adult Asthma

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs processed this record on August 21, 2017